Phase 3 underway
Evidence outlook · registrational
Registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2027-09-30.
Featured evidence outside covered markets: EvoPAR-BR01 (NCT06380751) · Advanced Breast Cancer · Phase 3 · ungraded PETRA (NCT04644068) · Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Additional Indications Below for Module 4 and 5, Non-small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer, Gastric Cancer, Biliary Cancer, Cervical Cancer, Endometrial Cancer, Small Cell Lung Cancer Only in Module 5 · Phase 1/2 · ungraded How the evidence outlook works ↗
Featured trials The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Advanced Breast Cancer · not a covered market · Outside covered markets · 1 Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Additional Indications Below for Module 4 and 5, Non-small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer, Gastric Cancer, Biliary Cancer, Cervical Cancer, Endometrial Cancer, Small Cell Lung Cancer Only in Module 5 · not a covered market · Outside covered markets · 1 not a covered market Outside covered markets · 1
Competitive landscape No competitors sharing a mechanism or indication in the current universe.
Upcoming events (12 total) Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (4) May 2027 (1) Phase 1/2 Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Additional Indications Below for Module 4 and 5 … Active not recruiting
Est. primary completion 2027-05-28 ·
NCT04644068 ·
CT.gov ↗ What to watch June 2027 (1) Phase 1 Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8 … Recruiting
Est. primary completion 2027-06-01 ·
NCT04005690 ·
CT.gov ↗ What to watch September 2027 (2) Phase 1/2 Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer, Squamous Non-Small Cell Lung Cancer Recruiting
Est. primary completion 2027-09-29 ·
NCT05123482 ·
CT.gov ↗ What to watch Phase 3 Metastatic Castration-Sensitive Prostate Cancer Active not recruiting
Est. primary completion 2027-09-30 ·
NCT06120491 ·
CT.gov ↗ What to watch 2028 (2) August 2028 (1) Phase 1/2 Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma Recruiting
Est. primary completion 2028-08-04 ·
NCT05797168 ·
CT.gov ↗ What to watch December 2028 (1) Phase 2 Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype, Lung Small Cell Carcinoma, I Subtype … Recruiting
Est. primary completion 2028-12-31 ·
NCT06769126 ·
CT.gov ↗ What to watch 2029 (2) January 2029 (1) Phase 1/2 Prostate Cancer Recruiting
Est. primary completion 2029-01-26 ·
NCT07336446 ·
CT.gov ↗ What to watch December 2029 (1) Phase 3 Advanced Breast Cancer Recruiting
Est. primary completion 2029-12-18 ·
NCT06380751 ·
CT.gov ↗ What to watch 2030 (1) March 2030 (1) Phase 1/2 Solid Tumours Recruiting
Est. primary completion 2030-03-29 ·
NCT07446855 ·
CT.gov ↗ What to watch 2031 (2) April 2031 (1) Phase 1/2 Metastatic Prostate Cancer Active not recruiting
Est. primary completion 2031-04-11 ·
NCT05367440 ·
CT.gov ↗ What to watch June 2031 (1) Phase 3 Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Not yet recruiting
Est. primary completion 2031-06-17 ·
NCT07711002 ·
CT.gov ↗ What to watch 2033 (1) March 2033 (1) Phase 3 Prostate Cancer Recruiting
Est. primary completion 2033-03-31 ·
NCT06952803 ·
CT.gov ↗ What to watch See the full readout calendar ↗
All registered studies Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.
Phase 3 (4) Phase 2 (1) Phase 1/2 (7) Phase 1 (7)